Helios is using options, not cash, to bridge from biotech promise to first commercial revenues. In its 29th paid stock-option grant, approved on June 17, the company said it wants directors, officers and employees focused on turning its ARDS drug candidate HLCM051 and related medical materials into sales as it moves into a phase of recovering research investment. Helios said HLCM051 is its most advanced program, with the FDA having agreed the design of a global Phase 3 trial and domestic preparation under way for an application for conditional, time-limited approval.
The 29th series can be exercised only if Helios wins domestic approval for HLCM051 for ARDS and records at least ¥1.5bn in revenue in any year through 2032. Management said that hurdle would rely mainly on launching HLCM051 in Japan and selling cell-culture supernatant produced in the manufacturing process as medical material. That is a long stretch from the last three years of revenue, which the company listed at ¥121mn, ¥560mn and ¥104mn. In other words, these options only pay if the science starts acting like a business.
Helios says paid options help it conserve cash while widening incentives beyond senior management. If the 29th series is fully exercised, it would amount to 12,135,600 shares, equal to 9.0% of shares outstanding and 6.5% on a fully diluted basis at the decision date. The exercise price is set at 10% of the previous trading day’s close, or ¥26.2 a share. The company also approved same-day 28th, 29th and 30th series grants, which together would amount to 14.0% dilution against shares outstanding. A separate paid 30th series for the chief executive adds extra milestones around licensing or sales of HLCM051, culture-supernatant sales, Phase 3 progress and market value above ¥100bn. This is still a compensation and capital-markets move, not approval for HLCM051, and the timing of any approval or commercialization remains uncertain.